MIRA (MIRA Pharmaceuticals Inc.) Nilai bisnis marang pendapatan

Logo perusahaan publik MIRA Pharma (MIRA)

MIRA Pharmaceuticals develops non-opioid treatments for neurological disorders by synthesizing cannabinoid analogs. Management serves as a key driver, implementing plant-based pain therapy standards and effectively attracting investment. The early stage of molecule development necessitates strict cost control, although cash levels remain healthy. The shift in the EV/Sales ratio on the GURU.Markets terminal chart confirms the market consensus, where the current parameter equals 0.00.

MIRA - Multiplikator EV/Sales MIRA Pharmaceuticals, Inc. ing rentang 23.11.2025 - 20.11.2026

MIRA (MIRA Pharmaceuticals, Inc.): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis wiwitan perusahaan:MIRA Pharmaceuticals
Produk seri mirapharmaceuticals.com

To assess the asset quality of MIRA Pharmaceuticals, it is critical to compare the business's market value with its ability to generate cash flow. Analyzing the change in the company's enterprise value to revenue, we see a current ratio of 0.00, which combines market capitalization and net debt, allowing for a determination of the premium paid for future sales of innovative non-opioid analgesics and the issuer's real cost of capital.